Filing Flows › Stoke Therapeutics (STOK) › Recalls, complaints & regulation
Stoke Therapeutics (STOK): clinical trials
Stoke Therapeutics (STOK) beyond its filings: 2 active clinical trials.
Stoke Therapeutics' latest quarter
Stoke Therapeutics, Q3 2026: revenue $11.3M (+6% year over year), operating margin -686.9%, net loss $73.6M, operating cash flow −$62.7M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Stoke Therapeutics have?
2 active studies on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.